Arkolith/Insider Trading/HALO/Form 4

Torley Helen

PRESIDENT AND CEO, DirectorHALOZYME THERAPEUTICS, INC. (HALO) · full profile →Form 4 · filed Mar 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.5M
Net Open-Market Flow
-$3.5M
Transactions
13
10 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2026Sell(S)7K$69.94$513K770K
Mar 4, 2026Option exercise(M)10K$12.07$121K778K
Mar 4, 2026Sell(S)3K$70.95$190K768K
Mar 3, 2026Option exercise(M)20K$12.07$241K788K
Mar 3, 2026Sell(S)13K$68.85$928K774K
Mar 3, 2026Sell(S)7K$69.33$452K768K
Mar 2, 2026Sell(S)15K$69.80$1.1M768K
Mar 2, 2026Sell(S)4K$69.20$284K784K
Mar 2, 2026Sell(S)578$70.46$41K768K
Mar 2, 2026Option exercise(M)20K$12.07$241K788K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)10K$12.07$121K152K
Mar 3, 2026Option exercise(M)20K$12.07$241K162K
Mar 2, 2026Option exercise(M)20K$12.07$241K182K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001159036-26-000032) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML